Observational studyBJS open2026
Preoperative carbohydrate antigen 19-9 as a prognostic biomarker in colorectal cancer with synchronous peritoneal metastasis: multicentre cohort study.
Observational study in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCurrently, no international guidelines recommend carbohydrate antigen 19-9 (CA19-9) as a biomarker in colorectal cancer in clinical practice, although it has been reported that tumour cells with high affinity for peritoneal cells strongly express CA19-9. The aim of this study was to determine the utility of preoperative serum CA19-9 levels in predicting prognosis in patients with colorectal cancer and synchronous peritoneal metastasis.
methodsPrognostic analyses were retrospectively performed in patients with colorectal cancer and synchronous peritoneal metastases who received treatment in 16 hospitals between 1991 and 2007 (Cohort 1). The categorization for CA19-9 and carcinoembryonic antigen were established based on the thresholds that minimized Akaike information criterion values for overall survival. A separate validation cohort of patients with synchronous peritoneal metastasis was prospectively registered across 28 institutions between 2012 and 2016 (Cohort 2) to validate these findings.
resultsA total of 689 patients were analysed in Cohort 1 and 144 in the validation Cohort 2. The categorized serum CA19-9 and carcinoembryonic antigen levels were significantly correlated with overall survival (P < 0.001 and P < 0.001, respectively). The median postoperative overall survival was 19.0 months for patients with a preoperative CA19-9 level < 100 U/ml compared with 4.1 months for those with a preoperative CA19-9 level of ≥ 10 000 U/ml. Using multivariable analysis, serum CA19-9, but not carcinoembryonic antigen, was an independent prognostic factor for overall survival. These results were confirmed in Cohort 2, revealing that the prognostic power of CA19-9 was superior to that of carcinoembryonic antigen.
conclusionsPreoperative serum CA19-9 outperformed carcinoembryonic antigen as an independent prognostic biomarker in patients with colorectal cancer and peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.